Zacks Investment Research upgraded shares of SINO BIOPHARMACEUT HKD0.025 (NASDAQ:SBMFF) from a hold rating to a buy rating in a research report released on Saturday. They currently have $1.00 price target on the stock.

According to Zacks, “Sino Biopharmaceutical Limited researches, develops, produces and sells biopharmaceutical products for the medical treatment of ophthalmia, as well as modernized Chinese medicine and chemical medicine for the treatment of hepatitis. Sino Biopharmaceutical Limited is headquartered in Wanchai, Hong Kong. “

SINO BIOPHARMACEUT HKD0.025 (NASDAQ:SBMFF) opened at 0.8965 on Friday. The company’s 50 day moving average price is $0.87 and its 200-day moving average price is $0.80. The company has a market capitalization of $6.65 billion and a P/E ratio of 23.5921. SINO BIOPHARMACEUT HKD0.025 has a 52 week low of $0.63 and a 52 week high of $0.93.

TRADEMARK VIOLATION WARNING: “SINO BIOPHARMACEUT HKD0.025 (SBMFF) Upgraded at Zacks Investment Research” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at

Get a free copy of the Zacks research report on SINO BIOPHARMACEUT HKD0.025 (SBMFF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for SINO BIOPHARMACEUT HKD0.025 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SINO BIOPHARMACEUT HKD0.025 and related companies with Analyst Ratings Network's FREE daily email newsletter.